References
- Sanders M . Inhalation therapy: an historical review. Prim. Care Resp. J.16(2), 71–81 (2007).
- Connor A , McDermottJ. Re-engineering the early development process for pulmonary drug delivery products. Ther. Deliv.4(8), 883–885 (2013).
- Onoue S , YamadaS. Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system?. Ther. Deliv.4(8), 887–889 (2013).
- Nokhodchi A , LarhribE. Overcoming the undesirable properties of dry-powder inhalers with novel engineered mannitol particles. Ther. Deliv.4(8), 879–882 (2013).
- Salomon JJ , GaleronP, SchulteNet al. Biopharmaceutical in vitro characterisation of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. Ther. Deliv. 4(8), 915–923 (2013).
- Shur J , PitchayajittipongC, RoguedaP, PriceR. Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers. Ther. Deliv.4(8), 925–937 (2013).
- Smutney CC , GrantM, KinseyPS. Device factors affecting pulmonary delivery of dry powders. Ther. Deliv.4(8), 939–949 (2013).
- Cipolla D , GondaI, Chan H-K. Liposomal formulations for inhalation. Ther. Deliv.4(8), 1047–1072 (2013).
- Ibrahim M , Garcia-ContrerasL. Mechanisms of absorption and elimination of drugs administered by inhalation. Ther. Deliv.4(8), 1027–1045 (2013).
- El-Gendy N , KaviratnaA, BerklandC, DharP. Delivery and performance of surfactant replacement therapies to treat pulmonary disorders. Ther. Deliv.4(8), 951–980 (2013).
- Wong J , KwokPCL, Chan H-K. Electrostatics in pharmaceutical aerosols for inhalation. Ther. Deliv.4(8), 981–1002 (2013).
- Mitchell JP , NagelMW. Improved laboratory test methods for orallyinhaled products. Ther. Deliv.4(8), 1003–1026 (2013).